Literature DB >> 22089488

ASCO-CAP guidelines for breast predictive factor testing: an update.

M Elizabeth Hale Hammond1.   

Abstract

This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor and Progesterone Receptor Testing by Immunohistochemistry, published in 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089488     DOI: 10.1097/PAI.0b013e31822a8eac

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  14 in total

1.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

2.  Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

Authors:  Li Ding; Zijin Zhang; Yan Xu; Yongqiang Zhang
Journal:  Bioengineered       Date:  2017-01-11       Impact factor: 3.269

3.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

4.  Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-07-04       Impact factor: 2.745

5.  Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.

Authors:  Asude Aksoy; Hatice Odabas; Serap Kaya; Oktay Bozkurt; Mustafa Degirmenci; Turkan O Topcu; Aydin Aytekin; Erkan Arpaci; Nilufer Avci; Kezban N Pilanci; Havva Y Cinkir; Yakup Bozkaya; Yalcin Cirak; Mahmut Gumus
Journal:  Saudi Med J       Date:  2017-02       Impact factor: 1.484

6.  Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.

Authors:  Rares Georgescu; Monica Boros; Denisa Moncea; Orsolya Bauer; Marius-Florin Coros; Adela Oprea; Cosmin Moldovan; Cristian Podoleanu; Simona Stolnicu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-09

7.  Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.

Authors:  Diego Caliari; Valentina Zappulli; Roberta Rasotto; Barbara Cardazzo; Federica Frassineti; Michael H Goldschmidt; Massimo Castagnaro
Journal:  BMC Vet Res       Date:  2014-09-25       Impact factor: 2.741

8.  Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.

Authors:  Yaewon Yang; Seock-Ah Im; Bhumsuk Keam; Kyung-Hun Lee; Tae-Yong Kim; Koung Jin Suh; Han Suk Ryu; Hyeong-Gon Moon; Sae-Won Han; Do-Youn Oh; Wonshik Han; Tae-You Kim; In Ae Park; Dong-Young Noh
Journal:  BMC Cancer       Date:  2016-07-21       Impact factor: 4.430

9.  A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry.

Authors:  Qianqian Guo; Kai Chen; Xiaojie Lin; Yi Su; Rui Xu; Yan Dai; Chang Qiu; Xue Song; Siying Mao; Qianjun Chen
Journal:  Oncotarget       Date:  2017-07-17

10.  Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.

Authors:  Wilbert Zwart; Paul J van Diest; Cathy B Moelans; Willemijne A M E Schrijver; Karianne Schuurman; Annelot van Rossum; Ton Peeters; Natalie Ter Hoeve
Journal:  Oncotarget       Date:  2017-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.